Differential methylation at the RELN gene promoter in temporal cortex from autistic and typically developing post-puberal subjects

Table 1 Brain tissue information for ASD patients and controls

Pair no.	Case no.^a	BA	Diagnosis	Age (years)^b	Sex	PMI (h)^c	Cause of death	Intellectual disability	Epilepsy	Other features	Drug therapies at time of death^d
1	AN11989 (B6677)	41/42	Autism	20	M	16	Cardiac arrest	Yes	Yes	–	Heart medication, Zoloft, clomipramine
2	AN08792 (B5173)	41/42	Autism	30	M	20	Gastrointestinal hemorrhage	Yes	Yes	Large ear lobes	Dilantin, Depakote, Tranxene bid, cisapride, clorazepate, folic acid, oxcarbazepine
3	AN00764 (B5144)	22	Autism	20	M	23.7	Trauma	Yes	No	–	None
4	AN17138 (B6294)	41/42	Autism	16	M	Unknown	Seizure	Unknown	Yes	Inherited 15q duplication	Topamax, Depakote, Allegra, Claritin, NuThera multivitamin
5	AN09730 (B6337)	22	Autism	22	M	25	Seizure	Yes	Yes	Intestinal lymphadenopathy, hypertrophic spleen, recurrent otitis	Lamictal, Zonegran, Neurontin, Abilify, flax seed oil, omega-3, multivitamin
6	AN01570 (B6184)	41/42	Autism	18	F	6.75	Seizure	Unknown	Yes	Focal slowing in the left parieto-occipital area	None
1	AN10833 (B5718)	41/42	Control	22	M	21.5	Unknown	No	No	–	None
2	B4211	41/42	Control	30	M	23	Cardiac arrhythmia	No	No	–	None
3	AN04432 (B3829)	22	Control	22	M	12	Central hepatic laceration	No	No	–	None
4	AN17425 (B6207)	22	Control	16	M	26	Ischemic heart attack	No	No	–	None
5	AN14368 (B6221)	41/42	Control	22	M	24	Unknown	No	No	–	None
6	UMB1541	22	Control	20	F	19	Head injuries	No	No	–	None

BA Brodmann area, PMI post-mortem interval
^aAutism Tissue Program identifier
^bMean age (±SD) for the autism group = 21.0±2.9, for controls = 22.0±1.8; t = −0.368, df = 10, p = 0.721
^cMean PMI (±SD) for the autism group = 18.2+3.2, for controls = 20.9±2.0, t = −0.707, df = 9, p = 0.497
^dPharmacological therapy from the last available report, dating back to less than a year prior to death

ISSN: 1866-1955